CN119258067A - 取代的哌啶化合物及其用途 - Google Patents
取代的哌啶化合物及其用途 Download PDFInfo
- Publication number
- CN119258067A CN119258067A CN202411462171.6A CN202411462171A CN119258067A CN 119258067 A CN119258067 A CN 119258067A CN 202411462171 A CN202411462171 A CN 202411462171A CN 119258067 A CN119258067 A CN 119258067A
- Authority
- CN
- China
- Prior art keywords
- azabicyclo
- oct
- represented
- fluoropyrimidin
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-122864 | 2020-07-17 | ||
| JP2020122864 | 2020-07-17 | ||
| PCT/JP2021/026649 WO2022014680A1 (ja) | 2020-07-17 | 2021-07-15 | 置換ピペリジン化合物及びその用途 |
| CN202180044081.3A CN115884971B (zh) | 2020-07-17 | 2021-07-15 | 取代的哌啶化合物及其用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180044081.3A Division CN115884971B (zh) | 2020-07-17 | 2021-07-15 | 取代的哌啶化合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119258067A true CN119258067A (zh) | 2025-01-07 |
Family
ID=79291962
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411459551.4A Pending CN119235864A (zh) | 2020-07-17 | 2021-07-15 | 取代的哌啶化合物及其用途 |
| CN202411462171.6A Pending CN119258067A (zh) | 2020-07-17 | 2021-07-15 | 取代的哌啶化合物及其用途 |
| CN202180044081.3A Active CN115884971B (zh) | 2020-07-17 | 2021-07-15 | 取代的哌啶化合物及其用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411459551.4A Pending CN119235864A (zh) | 2020-07-17 | 2021-07-15 | 取代的哌啶化合物及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180044081.3A Active CN115884971B (zh) | 2020-07-17 | 2021-07-15 | 取代的哌啶化合物及其用途 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11479552B2 (enExample) |
| EP (1) | EP4151277A4 (enExample) |
| JP (1) | JP7190612B2 (enExample) |
| KR (1) | KR20230040953A (enExample) |
| CN (3) | CN119235864A (enExample) |
| AR (1) | AR122973A1 (enExample) |
| AU (1) | AU2021308053A1 (enExample) |
| BR (1) | BR112022026161A2 (enExample) |
| CA (1) | CA3187835A1 (enExample) |
| CL (1) | CL2022003666A1 (enExample) |
| CO (1) | CO2022018446A2 (enExample) |
| IL (1) | IL299125B1 (enExample) |
| MX (1) | MX2022016388A (enExample) |
| PE (1) | PE20231103A1 (enExample) |
| PH (1) | PH12022553488A1 (enExample) |
| TW (1) | TWI888599B (enExample) |
| UA (1) | UA129636C2 (enExample) |
| WO (1) | WO2022014680A1 (enExample) |
| ZA (1) | ZA202213562B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ787541A (en) | 2019-11-25 | 2025-10-31 | Alkermes Inc | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| JP7591592B2 (ja) * | 2022-01-14 | 2024-11-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 置換ピペリジン化合物を含有する医薬 |
| MX2024008024A (es) * | 2022-01-14 | 2024-07-15 | Eisai R&D Man Co Ltd | Cristal de compuesto de piperidina sustituida, sales de compuesto de piperidina sustituida y cristales de estas. |
| TW202423404A (zh) * | 2022-10-07 | 2024-06-16 | 日商橘生藥品工業股份有限公司 | 環戊烷化合物 |
| EP4611745A1 (en) * | 2022-10-31 | 2025-09-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| AU2023395547A1 (en) | 2022-12-16 | 2025-06-26 | Daiichi Sankyo Company, Limited | 2-azabicyclo[3.1.1]heptane compound |
| TW202502342A (zh) | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| WO2025137359A1 (en) | 2023-12-20 | 2025-06-26 | Eisai R&D Management Co., Ltd. | Assay methods to identify a disease |
| WO2025229493A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG34208A1 (en) | 1995-03-01 | 1996-12-06 | Guy Andrew Vaz | Blast and fragment resistant polyurethane boot sole for safety footwear |
| CA2220036A1 (en) | 1995-05-05 | 1996-11-07 | Human Genome Sciences, Inc. | Human neuropeptide receptor |
| US6309854B1 (en) | 1996-12-17 | 2001-10-30 | Smithkline Beecham Corporation | Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72 |
| US6159605A (en) | 1997-02-18 | 2000-12-12 | Dainichiseika Color & Chemicals Mfg. Co., Ltd. | Ink-jet recording sheet |
| US5935814A (en) | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
| US6020157A (en) | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| KR100327888B1 (ko) | 1999-07-14 | 2002-03-09 | 정숭렬 | 도로포장 파손촉진 시험장치의 무선제어 시스템 |
| JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Ｍｓｄ株式会社 | 新規ピペリジン誘導体 |
| CA2584838A1 (en) | 2004-10-20 | 2006-05-04 | Neurosearch A/S | Novel diazabicyclic aryl derivatives and their medical use |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| TW201444849A (zh) * | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途 |
-
2021
- 2021-07-15 CA CA3187835A patent/CA3187835A1/en active Pending
- 2021-07-15 MX MX2022016388A patent/MX2022016388A/es unknown
- 2021-07-15 WO PCT/JP2021/026649 patent/WO2022014680A1/ja not_active Ceased
- 2021-07-15 UA UAA202204882A patent/UA129636C2/uk unknown
- 2021-07-15 AR ARP210101982A patent/AR122973A1/es unknown
- 2021-07-15 KR KR1020227044679A patent/KR20230040953A/ko active Pending
- 2021-07-15 PE PE2022003006A patent/PE20231103A1/es unknown
- 2021-07-15 CN CN202411459551.4A patent/CN119235864A/zh active Pending
- 2021-07-15 TW TW110126031A patent/TWI888599B/zh active
- 2021-07-15 BR BR112022026161A patent/BR112022026161A2/pt unknown
- 2021-07-15 AU AU2021308053A patent/AU2021308053A1/en active Pending
- 2021-07-15 CN CN202411462171.6A patent/CN119258067A/zh active Pending
- 2021-07-15 PH PH1/2022/553488A patent/PH12022553488A1/en unknown
- 2021-07-15 EP EP21842047.9A patent/EP4151277A4/en active Pending
- 2021-07-15 US US17/376,452 patent/US11479552B2/en active Active
- 2021-07-15 CN CN202180044081.3A patent/CN115884971B/zh active Active
- 2021-07-15 JP JP2022536446A patent/JP7190612B2/ja active Active
-
2022
- 2022-12-14 ZA ZA2022/13562A patent/ZA202213562B/en unknown
- 2022-12-14 IL IL299125A patent/IL299125B1/en unknown
- 2022-12-20 CO CONC2022/0018446A patent/CO2022018446A2/es unknown
- 2022-12-20 CL CL2022003666A patent/CL2022003666A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022026161A2 (pt) | 2023-01-31 |
| US20220017517A1 (en) | 2022-01-20 |
| IL299125A (en) | 2023-02-01 |
| TWI888599B (zh) | 2025-07-01 |
| PE20231103A1 (es) | 2023-07-19 |
| ZA202213562B (en) | 2023-10-25 |
| CA3187835A1 (en) | 2022-01-20 |
| CN119235864A (zh) | 2025-01-03 |
| EP4151277A4 (en) | 2024-06-26 |
| JP7190612B2 (ja) | 2022-12-15 |
| CO2022018446A2 (es) | 2023-03-07 |
| TW202216705A (zh) | 2022-05-01 |
| AR122973A1 (es) | 2022-10-19 |
| MX2022016388A (es) | 2023-01-30 |
| CL2022003666A1 (es) | 2023-05-26 |
| EP4151277A1 (en) | 2023-03-22 |
| JPWO2022014680A1 (enExample) | 2022-01-20 |
| KR20230040953A (ko) | 2023-03-23 |
| US11479552B2 (en) | 2022-10-25 |
| CN115884971B (zh) | 2024-11-05 |
| WO2022014680A1 (ja) | 2022-01-20 |
| CN115884971A (zh) | 2023-03-31 |
| IL299125B1 (en) | 2025-11-01 |
| PH12022553488A1 (en) | 2024-04-22 |
| UA129636C2 (uk) | 2025-06-18 |
| AU2021308053A1 (en) | 2023-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115884971B (zh) | 取代的哌啶化合物及其用途 | |
| TWI378101B (en) | Pyridine derivatives and their use in the treatment of psychotic disorders | |
| ES2609264T3 (es) | Formas sólidas que comprenden (-)-O-desmetilvenlafaxina y usos de las mismas | |
| TW201018663A (en) | Fluorene compound and pharmaceutical use thereof | |
| CN107257801A (zh) | 选择性bace1抑制剂 | |
| KR101800140B1 (ko) | 벤조티아졸론 화합물 | |
| EP4438602A1 (en) | Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof | |
| JP7591592B2 (ja) | 置換ピペリジン化合物を含有する医薬 | |
| RU2840772C1 (ru) | Замещенные пиперидиновые соединения и их применение | |
| HK40083601A (en) | Substituted piperidine compound and application thereof | |
| TW202340145A (zh) | 氘化有機化合物及其用途 | |
| TW202542144A (zh) | 取代哌啶化合物及其用途 | |
| EA045865B1 (ru) | Замещенные пиперидиновые соединения и их применение | |
| CN108368118B (zh) | 一种取代的稠合咪唑环化合物及其药物组合物 | |
| HK40083601B (zh) | 取代的哌啶化合物及其用途 | |
| CA2882877A1 (en) | Salts of benzothiazolone compound as beta-2-adrenoceptor agonist | |
| WO2025146480A1 (en) | 2-azabicyclo[2.1.1]hexane derivatives useful in the treatment of mitochondrial disorders | |
| JP2025526368A (ja) | Ｉｒａｋ３のリガンド指向性分解分子としての置換ピラゾリル－ピリジニル化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |